Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JamesK who wrote (571)	7/27/2021 2:13:44 PM
From: scaram(o)uche	Read Replies (1) of 684

Nice pointer, thanks! Looks like their burn is pronounced, and that 2022 is expected to be Burn City. I'm intrigued, but I do not yet understand the ASCO crash. Bought a few "place holder" shares... a reminder to do further research. Anybody have a pointer to any analysis? Looks like ardx (I don't follow) has qualified. From their 7/19 release..... "the FDA noted that a key issue is the size of the treatment effect and its clinical relevance." Embarrassing to FDA, given Biogen/aducanumab!?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next